Viral hepatitis C in 2014--the beginning of the end?

Rev Med Chir Soc Med Nat Iasi. 2014 Apr-Jun;118(2):272-8.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Global Health
  • Hepacivirus / isolation & purification
  • Hepacivirus / pathogenicity*
  • Hepatitis C / diagnosis*
  • Hepatitis C / drug therapy*
  • Hepatitis C / epidemiology
  • Hepatitis C / virology
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Interferon Type I / therapeutic use*
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use*
  • Prevalence
  • Proline / administration & dosage
  • Proline / adverse effects
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • Protease Inhibitors / therapeutic use
  • Romania / epidemiology
  • World Health Organization

Substances

  • Antiviral Agents
  • Interferon Type I
  • Oligopeptides
  • Protease Inhibitors
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline